| Literature DB >> 28509297 |
Takashi Morikawa1, Atsuhiro Yoshida2, Shinya Kobayashi3, Mikiko Shibata4, Masahiro Hamada4, Masatsugu Kishida4, Chizuko Kitabayashi4, Haruko Daga3, Yoshio Konishi4, Koji Takeda3, Masahito Imanishi4.
Abstract
A 76-year-old man with lung cancer and multiple metastases was admitted for purpura and rapidly progressive glomerulonephritis. Adenosquamous cell carcinoma of the lung had been diagnosed 6 months earlier. Two anti-cancer drug regimens had no effect. At admission, his survival with his malignancy was estimated to be several months. Renal biopsy revealed pauci-immune necrotizing crescentic glomerulonephritis (CrGN). Negative results were obtained for myeloperoxidase-anti-neutrophil cytoplasmic antibody (ANCA) and proteinase-3-ANCA by enzyme-linked immunosorbent assay, and for peripheral-ANCA and cytoplasmic-ANCA by indirect immunofluorescence. He was diagnosed with ANCA-negative pauci-immune CrGN. Although steroids were initiated, the patient died of renal failure and intestinal bleeding 2 weeks later. It was later found that cancer cells were positive for interleukin (IL)-6 and that serum IL-6 levels were significantly elevated, concomitantly with increased IL-8, granulocyte-colony stimulating factor and transforming growth factor-β levels. Some kinds of lung cancer are known to produce IL-6 that activate neutrophils and are related to ANCA-associated CrGN. It appears that IL-6 can activate neutrophils in the pathogenesis of ANCA-negative pauci-immune CrGN with lung cancer. Therapy that blocks IL-6 may prove to be effective in vasculitis and cancer-related symptoms in such cases.Entities:
Keywords: ANCA-negative crescentic glomerulonephritis; Interleukin-6; Lung cancer; Neutrophil
Year: 2013 PMID: 28509297 PMCID: PMC5413652 DOI: 10.1007/s13730-013-0058-1
Source DB: PubMed Journal: CEN Case Rep ISSN: 2192-4449